A
68.50
-0.15 (-0.22%)
| Previous Close | 68.65 |
| Open | 69.24 |
| Volume | 670,205 |
| Avg. Volume (3M) | 1,081,859 |
| Market Cap | 3,960,866,816 |
| Price / Sales | 105.90 |
| Price / Book | 9.01 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -211.46% |
| Operating Margin (TTM) | -847.56% |
| Diluted EPS (TTM) | -2.99 |
| Quarterly Revenue Growth (YOY) | -79.30% |
| Total Debt/Equity (MRQ) | 12.76% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | -114.70 M |
| Levered Free Cash Flow (TTM) | -10.43 M |
| Return on Assets (TTM) | -16.69% |
| Return on Equity (TTM) | -35.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Arcellx, Inc. | Mixed | Bearish |
AIStockmoo Score
2.3
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 2.25 |
|
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 14.50% |
| % Held by Institutions | 102.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gilead Sciences, Inc. | 31 Dec 2025 | 6,720,803 |
| Nea Management Company, Llc | 30 Sep 2025 | 3,045,262 |
| Ra Capital Management, L.P. | 30 Sep 2025 | 3,036,527 |
| Perceptive Advisors Llc | 30 Sep 2025 | 2,468,353 |
| Sr One Capital Management, Lp | 31 Dec 2025 | 2,346,630 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 1,250,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 130.00 (Canaccord Genuity, 89.78%) | Buy |
| Median | 105.00 (53.29%) | |
| Low | 100.00 (UBS, 45.99%) | Buy |
| 100.00 (Wells Fargo, 45.99%) | Buy | |
| Average | 110.00 (60.58%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 68.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 05 Feb 2026 | 105.00 (53.28%) | Buy | 66.94 |
| 08 Dec 2025 | 105.00 (53.28%) | Buy | 74.08 | |
| HC Wainwright & Co. | 04 Feb 2026 | 115.00 (67.88%) | Buy | 69.38 |
| UBS | 07 Jan 2026 | 100.00 (45.99%) | Buy | 65.01 |
| Wells Fargo | 22 Dec 2025 | 100.00 (45.99%) | Buy | 65.18 |
| Canaccord Genuity | 08 Dec 2025 | 130.00 (89.78%) | Buy | 74.08 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |